biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s): BIOAF

Healthcare Biotechnology

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.

TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs > The recent Option Grant.

<< Previous

Bullboard Posts

Next >>

Comment by KayakerBCon Aug 13, 2022 2:01pm

125 Views

Post# 34894125

RE:RE:RE:RE:RE:RE:RE:RE:The recent Option Grant.

....anything in the low tens of millions up front and mid hundreds of millions in milestones will be a disappointment....

Realistically, I think even that's high. Waaaaay high on the up front $$$.

And as I said in my last post.....

....if there will be an XB3-001 upfront payment anything remotely like what you expect, why is the current plan to pay for the upcoming Phase II study -- right before the NASDAQ listing -- with a financing? Why won't we have more than sufficient cash to fund it?....

<< Previous

Bullboard Posts

Next >>

Changing Europe’s dependency on HREE from China